Study 17 Give numbers of studies screened, assessed for eligibility, and included 12 (Figure selection in the review, with reasons for exclusions at each stage, ideally with a 1) flow diagram. Study 18 For each study, present characteristics for which data were extracted 12 (Table 1) characteristics (e.g., study size, PICOS, follow-up period) and provide the citations. Risk of bias 19 Present data on risk of bias of each study and, if available, any outcome 12 within studies level assessment (see item 12). (Appendix Table 2) Results of 20 For all outcomes considered (benefits or harms), present, for each study: (Table 1) individual (a) simple summary data for each intervention group (b) effect estimates studies and confidence intervals, ideally with a forest plot. Synthesis of 21 Present results of each meta-analysis done, including confidence 13 and 14 results intervals and measures of consistency. (Table 2 and 3) Risk of bias 22 Present results of any assessment of risk of bias across studies (see Item 12 and 15 across studies 15). (Appendix Table 2) Additional 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 13 and 14 analysis analyses, meta-regression [see Item 16]). (Appendix Table 3 - 6) DISCUSSION Summary of 24 Summarize the main findings including the strength of evidence for each 14 evidence main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at 16 review-level (e.g., incomplete retrieval of identified research, reporting bias). Conclusions 26 Provide a general interpretation of the results in the context of other 16 evidence, and implications for future research. FUNDING Funding 27 Describe sources of funding for the systematic review and other support 2 (e.g., supply of data); role of funders for the systematic review.
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 12 (Figure 1) Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 12 (Table 1) Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 12 (Appendix Table 2) Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. (Table 1) Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. 13 and 14 (Table 2 and 3) Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). 12 and 15 (Appendix Table 2) Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). 13 and 14 (Appendix Table 3 - 6) DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). 14 Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). 16 Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 16 FUNDING Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 2
IBD_2016_12_28_KAPLAN_IBD-D-16-00226_SDC1.docx